It has been demonstrated that the levels of Aβ1–42, p-Tau 181, and p-Tau 396 in blood NDEs significantly increased in AD than healthy individuals and can predict the progression of AD 10 years before the clinical stage (Fiandaca et al., 2015; Winston et al., 2016). Here, MAPT is linked to Alzheimer disease.